Senda Biosciences is developing drugs based on an understanding of intersystems biology the way that humans interact with bacteria and plants. The startup, founded by Flagship Pioneering, has added $55 million to advance its three lead programs to clinical testing next year.
Proceeds to advance company's pipeline of next-generation cytokine immunotherapies Laura Shawver, Christine Siu join as independent directors BASEL, Switzerland and SAN DIEGO, Calif., June 10
Bright Peak Therapeutics Announces $107 Million Series B Financing and Expanded Board of Directors | Comunicados | Edición USA efe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from efe.com Daily Mail and Mail on Sunday newspapers.
miRecule, Inc., a Gaithersburg MD-based biotech company focused on the development of RNA therapeutics, raised $5.7M in funding.
The round was led by Alexandria Venture Investments, with participation from Boutique Venture Partners, Pathway Bioventures, Alumni Ventures Group, and national angel investors, Additional funding came from the Maryland Momentum Fund and the FSHD Society.
The company intends to use the funds to bring its lead microRNA therapy (MC-30) to clinical development for head & neck cancer.
Led by CEO Anthony Saleh, miRecule leverages the DREAmiR™ discovery platform, which integrates genomic and clinical outcomes data from thousands of patients to identify underlying genetic drivers of disease, and then designs matching RNA therapeutics that directly correct those abnormalities.
Gross proceeds expected to include $60 million from a committed PIPE and up to $175 million held in trust Anticipated cash resources will fund eFFECTOR's .